Traws Pharma regains Nasdaq compliance with $2.5M equity rule; under monitoring until Feb 2026

Traws Pharma, Inc.

Received Nasdaq confirmation on Feb 25, 2025 of compliance with minimum $2.5M stockholders' equity requirement.
Subject to mandatory panel monitoring through Feb 25, 2026; future non-compliance may lead to delisting without cure period.
Closed $20M gross proceeds offering on Dec 30, 2024 to strengthen financial position.
CEO cites potential transformational year ahead with bird flu/influenza antiviral pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.